ClinicalTrials.gg
CompletedNCT00448513Updated Jul 16, 2013

Effects of Tea Catechin Extracts on Oxidative Damage

An interventional study of catechin extracts in Healthy, sponsored by University of Shizuoka. Completed at 1 site in Japan. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-16.

Sponsored by University of Shizuoka · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to clarify the effects of tea catechin extracts on the frequency changes of micronuclei in peripheral lymphocytes compared with other oxidative stress markers in late middle aged healthy volunteers

Read the detailed description

Experimental studies have revealed that tea catechin extracts induce preventive effects on oxidative stress, but there have been few clinical trials conducted to verify the effects. Also, there have been few clinical markers indicating oxidative damage, and therefore, more accurate and reliable markers have been expected. The study is designed for evaluating the effects of tea catechin extracts on the frequency changes of micronuclei in peripheral lymphocytes as the indicator of oxidative damage, compared with other oxidative stress markers in late middle aged healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • catechin
  • oxidative stress
  • chromosome damage
  • aged
03

In context

Lead sponsor

University of Shizuoka is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 40 to 65 years old
  • healthy volunteers
  • obtained written informed concent before participation

Exclusion criteria

Exclusion Criteria:

  • participant who is not able to refrain from drinking tea for 2 weeks during the study
  • participant taking supplements or herbal products including folate, vitamin B, C, E, coenzyme Q10, calcium, for 2 weeks before the study
  • participant taking supplements or herbal products including folate, vitamin E for 3 months before the study
  • participant possessing tea allergy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    catechin

    catechin capsule group

    Dietary Supplement: catechin extracts

Interventions

  • Dietary supplementcatechin extracts

    comparison with placebo

06

What researchers measure

Primary outcomes

  1. the frequency changes of micronuclei in peripheral lymphocytes

    Time frame: After seven days untervention

Secondary outcomes

  1. the change of markers of oxidative damage, as measured by 8-hydroxyguanosine (8-OHdG), vitamin C, folate, homocysteine

    Time frame: After seven days intervention

07

Study locations

1 site
  • Shizuoka General Hospital
    Shizuoka, 420-0881, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Aug 2009 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2007
First posted
Mar 19, 2007
Start
Jun 2007
Primary completionActual
Aug 2009
CompletionActual
Apr 2012
Last update
Jul 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00448513
Lead sponsor
University of Shizuoka
Responsible party
Sponsor
First posted
Mar 19, 2007
Start date
Jun 2007
Primary completion
Aug 2009
Completion
Apr 2012
Last update
Jul 16, 2013

Study contacts

Hiroshi Yamada, MD, PhD
principal investigator · University of Shizuoka

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion